1.Antibacterial activity of levofloxacin combined with fosfomycin against Staphylococcus aureus
Xiu-Jie SONG ; You-Ning LIU ; Hong-Mei JU
The Chinese Journal of Clinical Pharmacology 2009;25(6):505-508
Objective To investigate the in vitro effects of levofloxacin combined with fosfomycin upon 30 strains of clinical isolates of Staphylo-coccus aureus (15 strains methicillin resistant and 15 strains methicillin sensitive Staphylococcus aureus ) . Methods A checkerboard method that adhered to the recommendations of the National Committee for Clinical Laboratory Standards was applied to assess the synergism effect between levofloxacin and fosfomycin. The FIC index was calculated according to the results. Results The MIC_(50) was reduced significantly for the combination of levofloxacin plus fosfomycin against Staphylococcus aureus. The FIC indexes of methicillin sensitive Staphylococcus aureus (MSSA ) less than 0. 5, from 0. 5 to 1, from 1 to 2, more than 2 were 36. 4% ,63. 6% ,0,0 respectively. The FIC indexes of methicillin resistant Staphylococcus aureus ( MRSA) less than 0. 5 ,from 0. 5 to 1 ,from 1 to 2,more than 2 were 81. 8% , 18. 2% ,0,0, respectively. Conclusion In vitro the combination of subinhibitory concentration of levofloxacin and fosfomycin presented synergistic and additive effect There were no antagonism.
2.Observation on the long - term effectiveness and safety of juvenile myopia patients wearing orthokeratology
Xia LI ; Mao-Ju ZHANG ; Xiu-Sheng SONG
International Eye Science 2018;18(5):968-970
coefficient of variation, corneal endothelium hexagonal cell ratio, anterior corneal surface curvature ratio of horizontal(HK) and vertical curvature(VK) were not statistically significant before and after wearing for 6mo, 1, and 2a (P > 0. 05). The uncorrected visual acuity increased significantly, and the diopter decreased significantly after their wearing (P<0.05). There was no significant difference in axial length after wearing OK lens for 6mo,1,and 2a (P>0.05). CONCLUSION: The orthokeratology lenses can significantly increase uncorrected visual acuity and improve refractive power for juvenile myopia without severe corneal or conjunctival complications occurred, which has little influence on corneal endothelial cells and corneal thickness with a certain degree of safety.
3.Down-regulation of TopI by RNA interference reduces the drug-sensitivity of small cell lung cancer cell lines to topotecan.
Xiu-ju LIU ; Qi-sen GUO ; Qiong ZHANG ; Xian-rang SONG ; Yong-lei LIU ; Chen GUO
Chinese Journal of Oncology 2008;30(10):741-744
OBJECTIVETo investigate the expressions of TopI gene in small cell lung cancer cell line H446, and explore the influence of TopI on the chemosensitivity of the cell line to topotecan (TPT).
METHODSWestern blot was performed to detect the TopI expression in H446 cells. Lipofectamine 2000 was used for the transient transfection of H446 cells by siRNA, and the transfection efficacy was detected. TopI mRNA was analyzed by quantitative RT-PCR and TopI protein was detected by Western blot to selected effective siRNA. The drug-sensitivity to topotecan (TPT) was evaluated by MTT assay.
RESULTSTopI gene was expressed in H446 cells. Lipofectamine 2000 mediated the siRNA effectively (88.67%). Compared with its parental cells, RT-PCR results showed that TopI mRNAs in transfected cells were reduced by (95.7 +/- 1.6)%, (90.8 +/- 1.6)%, (96.1 +/- 2.7)% and (96.3 +/- 1.8)%, respectively, and decreased significantly at protein level. By MTT assay, the inhibition rate of TPT to H446 cells transfected by siRNA was lower than that of control group at same concentrations (P < 0.01).
CONCLUSIONsiRNAs can silence the expression of TopI and decrease the drug-sensitivity of H446 cells to TPT.
Antineoplastic Agents ; pharmacology ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; DNA Topoisomerases, Type I ; genetics ; metabolism ; Down-Regulation ; Drug Resistance, Neoplasm ; Humans ; Lung Neoplasms ; metabolism ; pathology ; RNA Interference ; RNA, Messenger ; metabolism ; RNA, Small Interfering ; genetics ; Small Cell Lung Carcinoma ; metabolism ; pathology ; Topotecan ; pharmacology ; Transfection
4.Prognostic factors in patients with stage III and IV non-small cell lung cancer.
Li-hua SONG ; Xian-rang SONG ; Mei-qin LIU ; Xi-qin ZHANG ; Li ZHENG ; Xiu-ju LI ; Pu-xiang LIU
Chinese Journal of Oncology 2004;26(6):345-348
OBJECTIVETo investigate the prognostic factors in non-small cell lung cancer (NSCLC) at stage III and IV and establish a reliable model of clinical prognostic index.
METHODSKaplan-Meier and Cox regression were used to analyze the relationship between the prognostic factors and survival time in 114 cases of NSCLC. The prognostic factors included clinical-pathological features and serum levels of cytokeratin fragment 19 (Cyfra21-1), CEA, neuron-specific enolase (NSE), CA125, interleukin-2 (IL-2) and soluble interleukin-2 receptors (sIL-2R).
RESULTSKaplan-Meier analysis showed that KPS, sex, disease stage, treatment, Cyfra21-1, sIL-2R and CA125 were related to prognosis. Multivariate analysis indicated that Cyfra21-1, stage and treatment were independent prognostic factors. When Cyfra21-1 > 3.5 mg/L, stage IV and chemotherapy < 3 cycles, the relative risk (RR) was 1.691, 2.229 and 3.035, respectively. In patients given 3 or more cycles of chemotherapy, serum Cyfra21-1, sIL-2R and stage at diagnosis were significantly independent prognostic factors. Three of these prognostic factors were used to establish a prognostic index (PI) model based on a simple algorithm: PI = Cyfra21-1 + sIL-2R + stage. The median survival period of patients with 3 or more cycles of chemotherapy were 18 months if PI = 0, 8 months if PI = 1 or 2, and 5 months if PI = 3.
CONCLUSIONThe serum Cyfra21-1, sIL-2R and disease stage in unresectable NSCLC were independent prognostic factors. PI calculated on the basis of Cyfra21-1, sIL-2R and stage is recommended to predict the survival period of NSCLC.
Antigens, Neoplasm ; blood ; Biomarkers, Tumor ; blood ; Carcinoma, Non-Small-Cell Lung ; drug therapy ; mortality ; pathology ; Female ; Follow-Up Studies ; Humans ; Keratin-19 ; Keratins ; Lung Neoplasms ; drug therapy ; mortality ; pathology ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Proportional Hazards Models ; Receptors, Interleukin-2 ; blood ; Survival Rate
5.Prognostic factors in patients with small cell lung cancer.
Li-hua SONG ; Xian-rang SONG ; Xi-qin ZHANG ; Jie-lin QI ; Xiu-ju LI ; He TIAN ; Bing BU
Chinese Journal of Oncology 2004;26(7):413-416
OBJECTIVETo investigate the prognostic factors of small cell lung cancer (SCLC) and establish a reliable model of clinical prognostic index.
METHODSKaplan-Meier and Cox regression were used to analyze the relationship between survival time and prognostic factors in 60 cases of SCLC. The prognostic factors included clinical and laboratory parameters, serum cytokeratin fragment 19 (CYFRA21-1), carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), CA125, interleukin-2 (IL-2) and soluble interleukin-2 receptors (sIL-2R).
RESULTSKaplan-Meier analysis showed that poor prognosis was in patients with KPS < 80 or extensive disease and unrelated to other clinical parameters such as age, sex and smoking index, and in patients with serum NSE > 30 micro g/L, CEA > 5.0 micro g/L, CA125 > 37 KU/L and sIL-2R > 500 KU/L. Serum IL-2 and CYFRA21-1 were also elevated, but had no significant prognostic value. Multivariate analysis indicated that serum NSE, stage and treatment of disease were independent prognostic factors. The three prognostic factors enabled establishment of a prognostic index (PI) based on a simple algorithm: PI = NSE (0 if < or = 30 micro g/L, 1 if > 30 microg/L) + stage (0 = LD, 1 = ED) + CEA (0 if < or = 5.0 microg/L, 1 if > 5.0 microg/L).
CONCLUSIONThe stage of disease, systemic treatment and the level of serum NSE are independent prognostic factors. Without considering the influence of treatment-related factors on survival, the levels of serum CEA, NSE and stage of disease before treatment are significant independent prognostic factors. PI calculated on the basis of CEA, NSE and stage is recommended to predict the survival of SCLC.
Adult ; Aged ; Biomarkers, Tumor ; blood ; Brain Neoplasms ; secondary ; Carcinoma, Small Cell ; mortality ; secondary ; therapy ; Female ; Follow-Up Studies ; Humans ; Liver Neoplasms ; secondary ; Lung Neoplasms ; mortality ; pathology ; therapy ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Prognosis ; Proportional Hazards Models ; Survival Rate
6.Heat impact upon the infectivity of hepatitis B virus in serum.
Xiu-xia SONG ; Li-wen JU ; Guo-rong WEI ; Qing-wu JIANG
Chinese Journal of Preventive Medicine 2011;45(8):723-726
OBJECTIVEThis article was to explore the impact of temperature on hepatitis B virus infectivity.
METHODSHBV positive serum with a HBV DNA titer of 1.33 × 10(8) copies/ml was aliquots into 23 Ep tubes with 1.5 ml, 100 µl in one tube.15 tubes were incubated at 37, 56 and 65°C for 0, 30, 60, 120 and 600 minutes, respectively. The other 8 tubes were incubated at 98°C for 0, 5, 10 and 30 minutes, respectively. Post-treated serum at all time points were selected to infect HepG-2 cell. When 18 hours after infection, these cells were extensively washed with phosphate buffered saline. Cells were harvested after the addition of fresh culture medium to culture cells for 48 hours. HBV DNA was detected by FQ-PCR.
RESULTSHBV DNA was detected in cells that were infected by serum at 37°C and 56°C for 30, 60, 120 and 600 minutes, respectively. The titers for the cells incubated at 37°C were (4.85 ± 1.71) × 10(5), (3.85 ± 1.76) × 10(5), (1.67 ± 0.67) × 10(5), (7.86 ± 1.03) × 10(4) copies/ml, and those for the cells incubated at 56°C were (4.01 ± 0.16) × 10(5), (9.77 ± 0.97) × 10(4), (6.36 ± 0.65) × 10(4), (5.05 ± 0.24) × 10(3) copies/ml at different incubation time points. For the cells incubated at 65°C for 60 and 120 minutes, HBV DNAs were (5.15 ± 7.28) × 10(3) and (7.56 ± 10.60) × 10(2) copies/ml, respectively, which were much lower than those in the controls cells ((6.79 ± 1.48) × 10(5) copies/ml). The results of HBV DNA were different (F = 104.4, P < 0.001) in groups treated with different temperature, and results of HBV DNA were also different (F = 144.0, P < 0.001) in groups processed for different period of time. Temperature and processing time had interaction (F = 23.6, P < 0.001). After heating at 98°C for 10 minutes and boiling for 5 minutes, the HBV DNA copy number ((3.02 ± 4.26) × 10(2), (4.31 ± 6.09) × 10(2) copies/ml) in infected cells decreased by about 10 folds than that in the control group ((6.79 ± 1.48) × 10(5) copies/ml). HBV DNAs were not detected in cells that were infected by serum which was heated at 98°C for 30 minutes and boiled for 10 minutes.
CONCLUSIONThe infectivity of HBV serum in vitro was relatively stable at low temperature, and it would lose its infectivity in short period of time at high temperature.
Hep G2 Cells ; Hepatitis B virus ; pathogenicity ; physiology ; Hot Temperature ; Humans ; Serum ; virology
7.Effect of mPGES-1 inhibitor MK886 on cell cycle of leukemia HL-60 cells.
Yi-Qing LI ; Song-Mei YIN ; Shuang-Feng XIE ; Xiu-Ju WANG ; Li-Ping MA ; Da-Nian NIE ; Yu-Dan WU
Journal of Experimental Hematology 2012;20(5):1072-1076
To investigate the effect of a microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor MK886 on cell cycle of the human acute myeloid leukemia HL-60 cells. HL-60 cells were treated with different concentration of MK886 (10, 25, 50 µmol/L) for 24 h. Flow cytometry, Western blot and ELISA were used to measure cell cycle, cyclin D1, mPGES-1, PGE(2), Akt, P-Akt and C-MYC. The results indicated that after treated with MK886, the percentage of HL-60 cells decreased in G(0)/G(1) phase and increased in S phase, and expressions of mPGES-1, cyclin D1, P-Akt and C-MYC and synthesis of PGE(2) decreased significantly. It is concluded that MK886 can arrest HL-60 cells in G(0)/G(1) phase, the mechanism of which is possibly associated to inhibition of mPGES-1 expression, reduction of PGE(2) synthesis, suppression of Akt phosphorylation and C-MYC expression, down-regulation of cyclin D1 expression.
Cell Cycle
;
drug effects
;
HL-60 Cells
;
Humans
;
Indoles
;
pharmacology
;
Intramolecular Oxidoreductases
;
antagonists & inhibitors
;
Leukemia
;
metabolism
;
pathology
;
Prostaglandin-E Synthases
8.Risk factors for extrauterine growth retardation at discharge in premature infants.
Yue-Ju CAI ; Yan-Yan SONG ; Zhi-Jian HUANG ; Jian LI ; Xu-Wen XIAO ; Jun-Ye QI ; Lan-Xiu WANG
Chinese Journal of Contemporary Pediatrics 2015;17(7):659-662
OBJECTIVETo study the incidence and risk factors for extrauterine growth retardation (EUGR) at discharge in premature infants.
METHODSA retrospective analysis was performed on 596 premature infants who were admitted to the neonatal intensive care unit between 2006 and 2010. These subjects were classified into EUGR (n=217) and non-EUGR groups (n=379) based on the body weight at discharge. The risk factors for the occurrence of EUGR were studied by multivariate logistic regression analysis.
RESULTSBased on the body weight, length, and head circumference, the incidence of EUGR at discharge was 36.4% (217 cases), 42.0% (250 cases), and 22.8% (136 cases), respectively. Low gestational age, low birth weight, intrauterine growth retardation (IUGR), delayed enteral feeding and complications of the respiratory system were identified as risk factors for EUGR (OR=6.508, 14.522, 5.101, 1.366, and 1.501, respectively).
CONCLUSIONSThe incidence of EUGR might be greatly decreased by strengthening the perinatal care, reducing the incidence of premature delivery and IUGR, undertaking early enteral feeding, and actively preventing postnatal complications.
Female ; Fetal Growth Retardation ; epidemiology ; etiology ; Humans ; Infant, Newborn ; Infant, Premature ; Logistic Models ; Male ; Retrospective Studies ; Risk Factors
9.Screening hepatocellular carcinoma autoantibodies by serological proteome analysis.
Ju-tao FENG ; Yin-kun LIU ; Zhi DAI ; Hai-jun ZHOU ; Hai-yan SONG ; Lun-xiu QIN ; Hong JIN ; Hao-jie LU ; Zhao-you TANG
Chinese Journal of Hepatology 2005;13(11):832-835
OBJECTIVETo screen hepatocellular carcinoma (HCC) autoantibodies as diagnostic biomarkers or therapy targets by serologic proteome analysis (SERPA).
METHODSTotal proteins extracted from human HCC cell line HCCLM3 were separated by two-dimensional electrophoresis (2-DE) and then transferred onto PVDF membranes, which were subsequently incubated with sera from HCC, hepatitis B virus (HBV) infected patients or healthy volunteers. All immuno-reactive protein spots on blot films were matched to those on 2-DE gel maps by image analysis and identified by matrix-assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS/MS).
RESULTS2-DE gel maps of HCCLM3 and corresponding blot films of good quality and reproducibility were established. The number of spots on HCCLM3 2-DE reference gel totaled 603 and those on HCC, HBV and healthy sera blotted films were 70.75+/-24.25, 68.5+/-23.44 and 41.38+/-15.05, respectively. Blot films of HCC and HBV groups had more spots than those of the healthy group (P < 0.05) while no significance was found between films of HCC and HBV groups. By identification, those HCC autoantibodies could be classified as nuclear proteins, cytoskeleton proteins, heat shock proteins and metabolic enzymes.
CONCLUSIONSerological proteome analysis is a high throughput technique for screening tumor autoantibodies. Those newly identified HCC associated tumor antigens and corresponding autoantibodies can be used in the early diagnosis or immuno-therapy of HCC.
Antibodies, Neoplasm ; analysis ; Autoantibodies ; analysis ; Carcinoma, Hepatocellular ; immunology ; Electrophoresis, Gel, Two-Dimensional ; Humans ; Liver Neoplasms ; immunology ; Proteomics ; methods ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ; Tumor Cells, Cultured
10.Cyclin D1, hTERT expression and telomerase activity in HL-60 and HL-60A cell lines and their significance.
Ke-Zhi HUANG ; Da-Nian NIE ; Song-Mei YIN ; Yi-Qing LI ; Shuang-Feng XIE ; Li-Ping MA ; Xiu-Ju WANG ; Yu-Dan WU
Journal of Experimental Hematology 2011;19(4):911-915
To observe the expression of cyclin D1, hTERT, and telomerase activity in MNC, HL-60, HL-60A and to explore their effects on leukemogenesis and drug-resistance, normal human peripheral blood mononuclear cells, HL-60 cells sensitive to adriamycin and HL-60A cells resistant to adriamycin were investigated. The cell cycle was analyzed by flow cytometry, and the apoptosis was analyzed by Annexin V-FITC(+) PI staining. Expressions of cyclin D1 and hTERT were determined by real-time PCR and Western blot. Telomerase activity was detected by TRAP-ELISA. The results indicated that the percentage of MNC, HL-60 and HL-60A in S phase was (10.21 + 2.11)%, (44.93 + 3.00)%, and (51.38 + 1.10)% respectively; the percentage of apoptosis cells was (16.14 + 2.13)%, (7.53 + 0.92)%, (4.15 + 0.96)% respectively; the expression of mRNA and protein for cyclin D1 and hTERT increased; the telomerase activities of HL-60 and HL-60A were higher (p = 0.000), whereas the difference between HL-60 and HL-60A was no statistically significant (p = 0.232); positive correlation between cyclin D1, hTERT and telomerase activity had been found (p < 0.01). It is concluded that the cells of S phase increased while the apoptotic cells decreased in HL-60 and HL-60A, especially in HL-60A, which may be due to the up-regulation of cyclin D1, hTERT and telomerase activity.
Cell Cycle
;
Cyclin D1
;
metabolism
;
HL-60 Cells
;
Humans
;
Leukemia
;
metabolism
;
Telomerase
;
metabolism